论文部分内容阅读
Background. Interferon plus ribavirin (IFN/Rib) therapy is currently standard treatment for chronic hepatitis C. Hemolytic anemia, however, is a serious side effect of this treatment, requiring reductions in or complete withdrawal of ribavirin. Methods. We retrospectively investigated the effect of the Kampo medicine Juzen-taiho-to (TJ-48), which contains bone marrow-stimulating compounds, on anemia in 67 patients with chronic hepatitis C, who received IFN/Rib therapy. Results. The reduction in hemoglobin levels was significantly ameliorated in TJ-48-treated patients (P < 0.05). Consequently, only 13%(4/32) of TJ-48-treated patients received altered doses of ribavirin, while the ribavirin dose had to be reduced or withdrawn in 43%(15/35) of patients in the absence of TJ-48 administration (P < 0.001). Conclusions. These results indica te the possibility that oral administration of TJ-48 supports IFN/Rib therapy without necessitating ribavirin reduction or withdrawal.
Background. Interferon plus ribavirin (IFN / Rib) therapy is currently standard treatment for chronic hepatitis C. Hemolytic anemia, however, is a serious side effect of this treatment, requiring reductions in or complete withdrawal of ribavirin. Methods. We retrospectively investigated the effect of the Kampo medicine Juzen-taiho-to (TJ-48), which contains bone marrow-stimulating compounds, on anemia in 67 patients with chronic hepatitis C, who received IFN / Rib therapy. Results. The reduction in hemoglobin levels was significantly ameliorated In TJ-48-treated patients (P <0.05). Only 13% (4/32) of TJ-48-treated patients received altered doses of ribavirin, while the ribavirin dose had to be reduced or withdrawn in 43% ( 15 of 35) of patients in the absence of TJ-48 administration (P <0.001). Conclusions. These results indica te the likely that oral administration of TJ-48 supports IFN / Rib therapy without necessating ribavirin reduction or withdrawal.